EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research

Michal Sternschuss iD, Michael Lattanzi iD, Emily Vertosick, Mia Austria iD, Sené Martin, Ashley Regazzi iD, Michael T Buckely iD, Joseph Lengfellner, Gregory J Riely iD, David B Solit iD, Jonathan E Rosenberg iD, Gopa Iyer iD und 4 weitere

JCO Oncology Practice · 2025

DOI: 10.1200/op-24-01041 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Michal Sternschuss und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Informed Consent, Telemedicine, Biomedical Research, Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Telemedicine is increasingly used in oncology research including informed consent discussions, but data evaluating the potential impact of telemedicine on the quality of informed consent are scarce. METHODS Consecutive patients with genitourinary malignancies who underwent informed consent discussions for biomarker (next-generation sequencing) or therapeutic (phase I to III) clinical studies at the Memorial Sloan Kettering Cancer Center were asked to complete modified versions of the validated Quality of Informed Consent (QuIC) questionnaire evaluating objective (QuIC A) and subjective (QuIC B) understanding. The method used for the informed consent discussion (in-person or telemedicine) was at the physician's discretion. QuIC scores were compared between telemedicine and in-person cohorts using separate linear regression models for QuIC A and B scores and for biomarker and therapeutic protocols. Cochran's Q was calculated to evaluate heterogeneity between biomarker and therapeutic protocols. RESULTS Of 320 eligible patients approached between January 2021 and July 2022, 239 patients completed the QuIC questionnaires after informed consent discussion for biomarker (n = 128) or therapeutic (n = 111) protocols, conducted via telemedicine (n = 49) or in person (n = 190). We did not find evidence that telemedicine and in-person consent differed between the biomarker and therapeutic studies for either QuIC A or B (heterogeneity P = .13 and P = .5, Respectively), and so the main analyses combined both study types. There were no differences between groups for QuIC A (adjusted difference, –1.3 [95% CI, –4.6 to 1.9]; P = .4), but QuIC B scores were significantly higher for telemedicine versus in-person consent for the therapeutic cohort (adjusted difference, –5.2 [95% CI, –10.3 to –0.01]; P = .049). CONCLUSION Our results support the use of telemedicine for informed consent discussions in clinical cancer research studies of biomarkers and clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Informed ConsentTelemedicineBiomedical ResearchNeoplasmsHumansMaleFemaleMiddle AgedAgedSurveys and QuestionnairesAdult

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
  • Texas Oncology, Austin, TX.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Research and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Michal Sternschuss, Michael Lattanzi, Mia Austria, Ashley Regazzi, Michael T Buckely, Gregory J Riely, David B Solit, Jonathan E Rosenberg, Gopa Iyer, Peter D Stetson, Michael J Morris, Andrew J Vickers, Samuel A Funt

Förderung

  • NCI NIH HHS

Zitieren

APA

Sternschuss, M., Lattanzi, M., Vertosick, E., Austria, M., Martin, S., Regazzi, A., Buckely, M. T., Lengfellner, J., Riely, G. J., Solit, D. B., Rosenberg, J. E., Iyer, G., Stetson, P. D., Morris, M. J., Vickers, A. J., & Funt, S. A. (2025). Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research. JCO Oncology Practice. https://doi.org/10.1200/op-24-01041

Vancouver

Sternschuss M, Lattanzi M, Vertosick E, Austria M, Martin S, Regazzi A, et al. Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research. JCO Oncology Practice. 2025. doi:10.1200/op-24-01041

BibTeX
@article{Sternschuss2025,
  author = {Sternschuss, Michal and Lattanzi, Michael and Vertosick, Emily and Austria, Mia and Martin, Sené and Regazzi, Ashley and Buckely, Michael T and Lengfellner, Joseph and Riely, Gregory J and Solit, David B and Rosenberg, Jonathan E and Iyer, Gopa and Stetson, Peter D and Morris, Michael J and Vickers, Andrew J and Funt, Samuel A},
  title = {Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-24-01041}
}
Kostenlos starten →